Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Lung02
2021-005879-40Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Started Apr 2022; status: active.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2021-005879-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005879-40.